“The present problem has uncovered some structural weaknesses from the EU’s medicines offer chain and also a substantial dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She encouraged that offer chain issues be resolved in an EU pharmaceutical approach envisioned to generally be launched by the end wi